Cardiac Troponin Market Report 2026

The cardiac troponin market size has grown rapidly in recent years. It will grow from $4.24 billion in 2025 to $4.68 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to increasing prevalence of acute coronary syndromes, expansion of emergency cardiac care services, adoption of biomarker-based diagnostics, improvements in laboratory testing accuracy, growth of hospital diagnostic infrastructure.

The cardiac troponin market size is expected to see rapid growth in the next few years. It will grow to $6.92 billion in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to increasing demand for rapid cardiac diagnostics, rising adoption of decentralized testing solutions, expansion of home-based cardiac monitoring, growing use of ai-supported diagnostic interpretation, increasing focus on early intervention strategies. Major trends in the forecast period include increasing adoption of high-sensitivity troponin assays, rising use of point-of-care cardiac testing, growing integration of automated laboratory diagnostics, expansion of rapid rule-in and rule-out protocols, enhanced focus on early cardiac injury detection.

The rising prevalence of heart-related conditions is expected to drive the growth of the cardiac troponin market in the coming years. Heart-related conditions include various cardiovascular diseases, such as coronary artery disease, heart failure, arrhythmias, and congenital heart defects, which impact the structure and function of the heart. The growing occurrence of these conditions is fueled by factors like aging populations, sedentary lifestyles, unhealthy dietary habits, and increasing rates of obesity and hypertension. Cardiac troponin plays a key role in diagnosing heart-related conditions, acting as a highly sensitive biomarker for detecting heart muscle damage, especially during heart attacks and other cardiac events. For example, in October 2024, the Centers for Disease Control and Prevention, a US-based federal agency, reported that in 2023, 919,032 people died from cardiovascular disease, accounting for 1 in every 3 deaths. Consequently, the increasing prevalence of heart-related conditions is expected to drive the growth of the cardiac troponin market.

Major companies in the cardiac troponin market are emphasizing the development of new technologies, such as human serum-based quality control, to ensure precise and reliable high-sensitivity troponin testing through multi-analyte controls. Human serum-based quality control in cardiac troponin testing maintains test accuracy and reliability by utilizing human serum with established troponin concentrations to validate assay performance. For example, in May 2023, Bio-Rad Laboratories, Inc., a US-based biotechnology research company, launched Cardiac Advance, a four-level, multi-analyte quality control specifically designed for high-sensitivity troponin testing. These liquid, human-serum-based controls are provided in InteliQ 3-mL tubes, Liquichek 3-mL standard, and 2.5-mL compact vials. The controls include 10 cardiac analytes, such as troponin, CK-MB, BNP/proBNP, and myoglobin, and are compatible with Siemens and Roche testing platforms. The products are available in the U.S., Europe, and selected Asian markets.

In January 2025, bioMérieux, a France-based provider of in vitro diagnostics and immunoassay solutions, acquired SpinChip Diagnostics ASA for an undisclosed amount. Through this acquisition, bioMérieux aims to accelerate the commercialization of SpinChip’s point-of-care immunoassay platform and enhance its presence in rapid diagnostics, particularly for cardiac care and acute-care biomarkers. SpinChip Diagnostics ASA is a Norway-based healthcare company developing a microfluidic, cartridge-based point-of-care diagnostics platform capable of delivering high-sensitivity cardiac troponin I and other immunoassays from a small blood sample within minutes.

Major companies operating in the cardiac troponin market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Becton Dickinson and Company, Laboratory Corporation of America Holdings (Labcorp), bioMérieux SA, Beckman Coulter Inc., QuidelOrtho Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Radiometer Medical ApS, Randox Laboratories Ltd., Fujirebio Diagnostics Inc., Meso Scale Diagnostics LLC., Singulex Inc., Diazyme Laboratories Inc., Response Biomedical Corporation, Eurolyser Diagnostica GmbH, LifeSign LLC.

North America was the largest region in the cardiac troponin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac troponin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiac troponin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cardiac troponin market by increasing costs of imported reagents, assay kits, analyzers, and diagnostic instrumentation used in laboratory and point-of-care testing. Hospitals and diagnostic laboratories in North America and Europe are most affected due to reliance on imported consumables, while Asia-Pacific faces pricing pressure on exported diagnostic products. These tariffs are raising testing costs and affecting procurement budgets. However, they are also encouraging local production of reagents, regional manufacturing of diagnostic kits, and diversification of supply chains to enhance test availability and cost stability.

The cardiac troponin market research report is one of a series of new reports that provides cardiac troponin market statistics, including cardiac troponin industry global market size, regional shares, competitors with a cardiac troponin market share, detailed cardiac troponin market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac troponin industry. This cardiac troponin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cardiac troponin is a group of proteins present in the heart muscle (myocardium) that help regulate heart contractions. These troponins are part of the muscle fiber proteins responsible for controlling the interaction between actin and myosin, which are crucial for muscle contraction. They serve as biomarkers used to detect heart injury, particularly heart attacks.

The primary types of cardiac troponin are troponin I and troponin T. Troponin I is a protein found in heart muscle cells that helps regulate muscle contractions, and elevated levels of troponin I in the blood can signal heart injury or stress, making it vital for precise cardiac diagnostics. Testing is conducted in laboratory settings as well as through point-of-care (PoC) testing for conditions such as acute coronary syndrome, myocardial infarction, congestive heart failure, and more. The end users include hospitals, diagnostic centers, homecare settings, and other healthcare facilities.

The cardiac troponin market consists of sales of diagnostic assays, test kits, point-of-care testing devices, and high-sensitivity troponin tests. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.